ResearcherGlasgow Royal InfirmaryNo recent work listed
Colin William Steele
Matched on ORCID iD 0000-0001-8518-1223; OpenAlex author ID A5070656562. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper
Papers 8
- The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
- CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
- Targeting inflammation in pancreatic cancer: Clinical translation. Co-author DOI 10.4251/wjgo.v8.i4.380↗
- RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. First author DOI 10.1093/jnci/djv204↗
- Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
- Exploiting inflammation for therapeutic gain in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.24↗
- Timing is everything: Brca2 and p53 mutations in pancreatic cancer. First author DOI 10.1053/j.gastro.2011.02.026↗
- Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e3182218ffb↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nigel Balfour Jamieson · 7 shared papers, 2011–2019 · strength 0.36
- Paper Targeting inflammation in pancreatic cancer: Clinical translation. DOI 10.4251/wjgo.v8.i4.380↗
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. DOI 10.1093/jnci/djv204↗
- C. Ross Carter · 5 shared papers, 2013–2016 · strength 0.25
- Paper Targeting inflammation in pancreatic cancer: Clinical translation. DOI 10.4251/wjgo.v8.i4.380↗
- Paper RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. DOI 10.1093/jnci/djv204↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Jennifer P. Morton · 5 shared papers, 2011–2019 · strength 0.23
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper Timing is everything: Brca2 and p53 mutations in pancreatic cancer. DOI 10.1053/j.gastro.2011.02.026↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Owen James Sansom · 5 shared papers, 2011–2019 · strength 0.23
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper Timing is everything: Brca2 and p53 mutations in pancreatic cancer. DOI 10.1053/j.gastro.2011.02.026↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Colin J. McKay · 4 shared papers, 2011–2015 · strength 0.17
- Paper RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. DOI 10.1093/jnci/djv204↗
- Paper Exploiting inflammation for therapeutic gain in pancreatic cancer. DOI 10.1038/bjc.2013.24↗
- Paper Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. DOI 10.1097/mpa.0b013e3182218ffb↗
- Peter J. Bailey · 3 shared papers, 2015–2019 · strength 0.15
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Paper Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abro… DOI 10.15252/emmm.201404827↗
- David Kuang-Fu Chang · 3 shared papers, 2015–2019 · strength 0.15
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Paper Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abro… DOI 10.15252/emmm.201404827↗
- Andrew Victor Biankin · 3 shared papers, 2015–2019 · strength 0.15
- Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Paper Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abro… DOI 10.15252/emmm.201404827↗
- Simon T. Barry · 2 shared papers, 2016–2019 · strength 0.11
- Thomas R. Jeffry Evans · 2 shared papers, 2015–2016 · strength 0.08
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014↗
- Paper Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abro… DOI 10.15252/emmm.201404827↗
- Karin A. Oien · 2 shared papers, 2011–2015 · strength 0.07
- Syed Haider · 1 shared paper, 2019 · strength 0.07
- Kate M. Moore · 1 shared paper, 2019 · strength 0.07
- Claire S. Reader · 1 shared paper, 2019 · strength 0.07
- Rita Teresa Lawlor · 1 shared paper, 2019 · strength 0.07
- Claude Chelala · 1 shared paper, 2019 · strength 0.07
- Hemant Mahendrakumar Kocher · 1 shared paper, 2019 · strength 0.07
- Aldo Scarpa · 1 shared paper, 2019 · strength 0.07
- John F. Marshall · 1 shared paper, 2019 · strength 0.07
- Lavanniya K. P. Velu · 1 shared paper, 2015 · strength 0.05
- Donald C. McMillan · 1 shared paper, 2015 · strength 0.05
- Mona Foth · 1 shared paper, 2016 · strength 0.04
- Juliana B. Candido · 1 shared paper, 2016 · strength 0.04
- Janine Terra Erler · 1 shared paper, 2015 · strength 0.04
- Caroline J. Springer · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.